$ALEC SEC Filings

Alector, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule I hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC and BTIG, LLC are acting as representatives...

Disposed of 2,421,197 Employee Stock Option (right to buy) (Disposition to Issuer) · Granted 2,421,197 Employee Stock Option (right to buy) · Received 217,500 shares as a grant or award · 1 more

Received 44,567 shares as a grant or award · Granted 190,000 Employee Stock Option (right to buy)

Disposed of 87,385 Employee Stock Option (right to buy) (Disposition to Issuer) · Granted 87,385 Employee Stock Option (right to buy) · Received 55,555 shares as a grant or award · 1 more

On October 13, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Alector, Inc. (“Alector” or the “Company”) approved an option repricing. The repricing generally applied to stock options to purchase shares of the commo...

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Sold 656 shares ($1.8K) · Sold 5,165 shares ($13.8K) · Sold 3,625 shares ($9.09K)

Sold 72,606 shares ($193K)

Sold 29,251 shares ($77.9K)

Gave 1,050,000 shares as a gift · Acquired 1,050,000 shares (Gift)